Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anemia Associated With Chronic Kidney Disease | Drug: Vadadustat Drug: Darbepoetin alfa Drug: Epoetin alfa | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 46 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease |
Actual Study Start Date : | May 28, 2019 |
Actual Primary Completion Date : | May 5, 2020 |
Actual Study Completion Date : | July 15, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Vadadustat 600 mg
Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.
|
Drug: Vadadustat
oral 150 mg tablet
Other Name: AKB-6548
|
Experimental: Vadadustat 750 mg
DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.
|
Drug: Vadadustat
oral 150 mg tablet
Other Name: AKB-6548
|
Experimental: Vadadustat 900 mg
DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.
|
Drug: Vadadustat
oral 150 mg tablet
Other Name: AKB-6548
|
Erythropoiesis-stimulating agent
Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.
|
Drug: Darbepoetin alfa
solution intravenous injection
Drug: Epoetin alfa solution for intravenous injection
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Research Site | |
Escondido, California, United States, 92025 | |
United States, Colorado | |
Research Site | |
Denver, Colorado, United States, 80230 | |
United States, Florida | |
Research Site | |
Fort Lauderdale, Florida, United States, 33308 | |
Research Site | |
Miami Beach, Florida, United States, 33140 | |
Research Site | |
Miami, Florida, United States, 33133 | |
Research Site | |
Orlando, Florida, United States, 32809 | |
United States, Missouri | |
Research Site | |
Kansas City, Missouri, United States, 64111 | |
United States, Oklahoma | |
Research Site | |
Midwest City, Oklahoma, United States, 73130 | |
United States, Rhode Island | |
Research Site | |
Providence, Rhode Island, United States, 02903 | |
United States, Tennessee | |
Research Site | |
Chattanooga, Tennessee, United States, 37404 |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | June 18, 2019 | ||||
First Posted Date ICMJE | June 19, 2019 | ||||
Last Update Posted Date | September 16, 2020 | ||||
Actual Study Start Date ICMJE | May 28, 2019 | ||||
Actual Primary Completion Date | May 5, 2020 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease | ||||
Official Title ICMJE | A Phase 1b, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease | ||||
Brief Summary | This study will be conducted to assess the pharmacokinetics of vadadustat 600, 750, and 900 milligrams daily, and intravenous erythropoiesis-stimulating agent (darbepoetin alfa or epoetin alfa), in hemodialysis participants with anemia associated with chronic kidney disease. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE | Anemia Associated With Chronic Kidney Disease | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE |
46 | ||||
Original Estimated Enrollment ICMJE |
35 | ||||
Actual Study Completion Date ICMJE | July 15, 2020 | ||||
Actual Primary Completion Date | May 5, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03992066 | ||||
Other Study ID Numbers ICMJE | AKB-6548-CI-0034 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Responsible Party | Akebia Therapeutics | ||||
Study Sponsor ICMJE | Akebia Therapeutics | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | Akebia Therapeutics | ||||
Verification Date | September 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |